The U.S. Food and Drug Administration granted enVVeno Medical Corp. (NASDAQ:NVNO) Investigational Device Exemption (IDE) approval to begin a pivotal U.S. study for its non-surgical venous valve, a first-ever for this type of device and potentially opening up a market of 3 million American patients.
In a "What This Means" segment, enVVeno Medical's Chief Executive Officer Robert Berman discussed the IDE approval, which is for the company's enVVe valve system designed to treat severe Deep Venous Insufficiency (DVI), the company announced Tuesday.
The enVVe system is a bioprosthetic (tissue-based) valve delivered via a transcatheter, designed to act as a one-way valve to improve blood flow back to the heart. DVI occurs when valves in the leg veins are damaged, leading to poor blood flow. The company states the procedure can be performed under light sedation without requiring an overnight hospital stay.
This IDE approval is a critical step for the clinical-stage company, significantly de-risking its path to potential commercialization. For investors, the approval positions enVVeno Medical with a first-mover advantage in a large, unaddressed market, as there are currently no effective, non-surgical treatments for DVI. The company, which is not yet generating revenue, sees this as a major step toward capturing a significant share of the estimated $3 billion market opportunity.
This article is for informational purposes only and does not constitute investment advice.
